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Abstract 
A rapid, specific and sensitive reverse phase high performance liquid chromatographic (RP-HPLC) 
method was developed for the determination of Tolperisone Hydrochloride (TOLP) in bulk and tablet 
dosage form. The method involved an isocratic elution of TOLP on C18 column (250 X 4.6 mm, 5 µm) 
using a mobile phase composition of acetonitrile: 20 mM ammonium acetate buffer containing 0.1% 
triethyl amine (55:45 v/v) (pH 4.0 adjusted by glacial acetic acid), at a 1.0 ml/min flow rate. The 
analyte was monitored at 260 nm wavelength. The retention time for tolperisone was found to be 2.50 
min. Linearity was established in range of 12.5 - 100 µg/ml with correlation coefficient 0.999. The % 
recovery was obtained as 98.38 – 101.58 %. The detection limit and quantitation limit were found to 
be 0.172 and 0.521 respectively. This method can be successfully employed for quantitative analysis 
of TOLP in bulk and pharmaceutical dosage form as its accuracy, precision, specificity and 
reproducibility.  
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1. Introduction 
TOLP, chemically 2-methyl-1-(4-
methylphenyl)-3-(1-piperidyl) propan-1-one 
monohydrochloride, is a piperidine derivative1,2 
(Figure 1). It has a specific relaxant effect on 
disabling neuromuscular spasms and thereby 
significantly improves patients’ mobility without 
any sedative side effects3. TOLP exerts its spinal 
reflex inhibitory action predominantly via a pre 
synaptic inhibition of the transmitter release 
from the primary afferent endings via a 
combined action on voltage-gated sodium and 
calcium channels4. It is only with Sanochemia’s 
developments, now licensed to Avigen, that the 
potential of TOLP can be fully utilized3. TOLP 
has the unique property of mediating muscle 
relaxation without concomitant sedation and it 
does not cause incoordination, weakness and 
mental confusion or withdrawal phenomena, in 
contrast to other muscle relaxants5.  
Figure 1: Chemical structure of TOLP 
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Japanese Pharmacopoeia suggests a 
potentiometric titration for the determination of 
TOLP in bulk6. A number of methods such as 
colorimetry7, HPLC8, LCMS9 have been 
reported for the quantitative estimation of 
TOLP. Potentiometric titration is an accurate but 
highly tedious method and no other official 
methods have been reported. Also reported 
methods have some demerits i.e. long run time, 
somewhat higher use of hazardous solvents. 
Hence it was decided to develop and validate a 
sensitive, accurate and rapid RP-HPLC method 
for determination of TOLP in bulk and 
pharmaceutical dosage form so as to fulfill the 
requirements of routine analysis in quality 
control department of pharmaceutical company. 
In the present work the RP-HPLC method is 
emphasized for the estimation of TOLP.  
 
2. EXPERIMENTAL 
2.1 Materials and methods: TOLP was 
procured as a gratis sample from Themis 
Medicare Pvt. Ltd., Vapi, Gujarat. The chemical 
structure and purity of obtained TOLP were 
authenticated by Fourier Transform Infrared 
Spectroscopy (FT-IR) and melting point 
measurement. HPLC grade acetonitrile, 
ammonium acetate, triethyl amine (TEA), 
glacial acetic acid and water (Merck Ltd., 
Mumbai, India) were used in proposed research 
work. The TOLP tablets claimed to contain 150 
mg were obtained from local market (Tolpidol®, 
Themis Medicare and Tolfree®, Zydus Cadila). 
2.2 Instrumentation and chromatographic 
conditions: Perkin Elmer HPLC system has 
been employed to develop this method. System 
consists of a quaternary gradient pump (LC-
200), manual loop injector (Rheodyne injector 
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with fix 20 µl capacity), degasser unit and UV-
visible detector (Series 200 LC). 
Chromatographic separations were carried out 
using the C18 column (250 X 4.6 mm, I.D. 5 µm) 
purchased from Chromatopak analytical 
instrumentations Ltd., India. Mobile phase 
consisted of acetonitrile: 20 mM ammonium 
acetate buffer containing 0.1% Triethyl amine 
(55:45 v/v) (pH 4.0 adjusted by glacial acetic 
acid). Mobile phase was filtered through 0.45 µ 
nylon filter and degassed in ultrasonic bath for 
10 min before running the experiment. Flow rate 
was kept at 1 ml/min and the detection was 
carried out using 260 nm as detection 
wavelength.  
2.3 Preparation of mobile phase: Accurately 
weighed 1.54 gm ammonium acetate was 
dissolved in 900 ml of water. 1.0 ml TEA was 
added in it and then pH was adjusted to 4.0 with 
glacial acetic acid. The volume was made up to 
1000 ml with water. Prepared 20 mM 
ammonium acetate buffer containing 0.1% TEA 
(pH 4.0 adjusted by glacial acetic acid) was 
mixed with acetonitrile in the ratio of 55:45 v/v. 
Mixture was filtered through 0.45 µ nylon filter 
and sonicated for 10 minutes to degas the 
mixture. 
2.4 Standard stock solution of TOLP: A 25 
mg of standard TOLP was weighed and 
transferred to a 25 ml volumetric flask. 10 ml 
water was added in flask and sonicated for 10 
min. The volume was made up to the mark with 
water to give a solution containing 1000 µg/ml 
TOLP. 
2.5 Preparation of assay sample solution: 
Twenty tablets of TOLP were weighed and 
finely powdered. The powder equivalent to 25 
mg TOLP was accurately weighed and 
transferred to volumetric flask of 25 ml capacity. 
10 ml of water was transferred to volumetric 
flask and sonicated for 10 min. The flask was 
shaken and volume was made up to the mark 
with water. The above solution was filtered 
through 0.45µ nylon filter. 0.5 ml of aliquot was 
taken and transferred to volumetric flask of 10 
ml capacity. The volume was made up to the 
mark with the diluent to give a solution of 50 
µg/ml of TOLP. 
2.6 Method validation: Developed method was 
validated as per USP10 and ICH11 guidelines.  
2.6.1 System suitability: To assess system 
suitability of the method, the peak area, 
theoretical plates, tailing factor and retention 
time of six replicate injections of standard TOLP 
of concentration (50µg/ml) were used.  
2.6.2 Linearity: The linearity was analyzed 
through the standard curves ranging from 12.5 - 
100µg/ml [25% - 200% of target concentration 
of TOLP (50 µg/ml)] by diluting appropriate 
amounts of TOLP stock solution (1000µg/ml) 
with water and prepared in triplicate. Three 
calibration curves were prepared in the same day 
with the following concentrations (12.5, 25, 
37.5, 50, 75 and 100µg/ml). The linearity was 
evaluated by linear regression analysis, which 
was calculated by the least-square regression 
analysis. 
2.6.3 Specificity: The specificity of the method 
was checked by monitoring a standard solution 
of TOLP in presence of excipients of tablets at 
the same concentration levels as used in tablets 
using the method described in the procedure for 
calibration curve.  
2.6.4 Accuracy: Accuracy was determined by 
standard addition method i.e. addition of 80%, 
100% and 120% of target concentration (50 
µg/ml).  
2.6.5 Precision: Precision of the method was 
determined by repeatability (intraday precision) 
and intermediate precision (interday precision) 
of both standard and sample solutions. Precision 
was determined in six replicates of both TOLP 
standard solution (50µg/ml) and sample solution 
(50µg/ml) on the same day (intra-day precision) 
and for 3 consecutive days (inter-day precision). 
The results were expressed as % RSD of the 
measurements.  
2.6.6 Limit of Detection (LOD) and Limit of 
Quantitation (LOQ): LOD and LOQ were 
determined using calibration curve method 
according to ICH Q2B (R1) recommendations. 
The LOD (݇ = 3.3) and LOQ (݇ = 10) of the 
proposed method were calculated using the 
following equation: 
ܣ = ݇ ߪ / ܵ , 
Where, ܣ is LOD or LOQ, σ is the standard 
deviation of the response, and ܵ is the slope of 
the calibration curve.  
 
2.6.7 Reproducibility: The reproducibility was 
confirmed by measuring absorbance at different 
laboratory using another spectrophotometer by 
another analyst and the values obtained were 
evaluated using t- test.  
2.6.8 Robustness: It was determined by 
studying the effect of flow rate at 0.9 and 
1.1ml/min instead of 1.0 ml/min. The effect of 
mobile phase composition was assessed at (ACN 
: Buffer = 53:47v/v) and (ACN :  Buffer = 
57:43v/v) instead of (ACN : Buffer = 55:45v/v). 
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The %RSD of robustness testing under these 
conditions was calculated in all cases. 
 
3. Results and Discussion  
3.1 Method validation 
3.1.1 System suitability: The results of the 
system suitability parameters are shown in Table 
1, indicating the good performance of the system 
and better suitability for the analysis of drug. 
Table 1: System suitability characteristics of 
proposed method. 
Parameter Value  
Mean ±%RSD (n = 6) 
Acceptable 
Limit
Peak area (µV/s) 2203484.635±0.011 - 
Tailing factor 1.55±0.247 < 2 
Theoretical plate 3336±1.094 > 2000 
Retention time 
(min) 
2.50±0.035 - 
 
3.1.2 Linearity: The regression equation for 
TOLP was found ݕ = 37191x + 24225 by 
plotting peak area (y) versus the concentration 
(x) studied from 12.5 - 100µg/ml and the 
correlation coefficient, 0.999 was highly 
significant. Results of three calibration curves 
are shown in Table 3 and linearity curve is 
presented in Figure 2. 
Table 2: Area for linearity solutions at 260 
nm for TOLP 
Conc. 
(µg/ml) 
Area 
Mean ± S.D. (n = 3) 
% 
RSD
12.5 742302.002±113.841 0.017 
25 1214744.376±133.514 0.012 
37.5 1667319.627±1131.561 0.068 
50 2180484.725±136.602 0.012 
75 3072731.035±3816.042 0.124 
100 3909298.306±6177.201 0.159 
 
Figure 2: Linearity curve for TOLP 
concentration 12.5 – 100 µg/ml 
 
3.1.3 Specificity: A typical HPLC 
chromatogram of TOLP standard preparation 
and TOLP test sample are shown in Figure 3(a) 
and 3(b). The HPLC chromatograms recorded 
for the mixture of the inactive ingredients 
revealed no peaks within retention time around 
2.50 min and the peak purity was 99.99%. 
Figure 3(a) and 3(b) show that TOLP is clearly 
separated from the response of any interfering 
peak(s). 
 
Figure 3(a): Typical chromatograms of TOLP 
standard preparation 
 
 
 
Figure 3(b): Typical chromatograms of 
TOLP sample preparation 
 
 
 
3.1.4 Accuracy: The results of this study were 
expressed as % recoveries of the particular 
components in the samples. The % recovery of 
TOLP was obtained in range of 98.38 – 101.58 
%. The results shown in Table 3, indicate good 
accuracy of the proposed RP-HPLC method. 
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Table 3: Accuracy study of TOLP by standard addition method 
Amt of drug in 
sample (mg) 
Amt of std drug 
added (mg) 
Amt measured 
(mg) 
Amt recovered 
(mg) 
% 
Recovery 
Average of 
% Recovery
50 0 49.19 - - - 
50 40 90.09 40.09 100.23 
99.80 50 40 89.93 39.93 99.82 
50 40 89.74 39.74 99.35 
50 50 99.95 49.95 99.90 
100.54 
 50 50 100.62 50.62 101.24 
50 50 100.24 50.24 100.48 
50 60 110.61 60.61 101.01 
100.32 50 60 109.03 59.03 98.38 
50 60 110.95 60.95 101.58 
 
3.1.5 Precision:; The values of %RSD for 
intraday and interday variation are given in 
Table 4. In both cases, %RSD values were found 
well within 2% limit, indicating that the current 
method is repeatable.  
Figure 4(a): Typical chromatogram of TOLP at LOD concentration 
 
 
 
 
 
 
 
 
 
 
 
Table 4: Results of Repeatability (Intra-day) and Intermediate Precision (Inter-day) study of 
TOLP 
Sr. no. Conc. (µg/ml) Standard solution Sample solution 
  Intra-day 
precision 
Inter-day 
precision 
Intra-day 
precision 
Inter-day 
precision 
1 200 2203595.174 2204016.216 2204097.172 2204263.250 
2 200 2203762.637 2203651.764 2203546.587 2203941.746
3 200 2203195.423 2203685.420 2203929.486 2203599.112 
4 200 2203489.238 2203290.878 2203788.234 2204531.656 
5 200 2203981.457 2204281.992 2203425.143 2204687.003
6 200 2203421.263 2204078.295 2203363.639 2203091.280 
Mean  2203574.199 2203834.094 2203691.710 2204019.008 
SD  274.185 358.845 293.259 601.937 
%RSD  0.012 0.016 0.013 0.027 
 
3.1.6 Limit of Detection (LOD) and Limit of 
Quantitation (LOQ): The LOD and LOQ of 
TOLP by the proposed method were found 
0.172 µg/ml and 0.521 µg/ml, respectively. 
Figure 4(a) and 4(b) show the sensitivity of the 
current method. 
 
 
 
 
 
Figure 4(b): Typical chromatograms of 
TOLP at LOQ concentration. 
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3.1.7 Reproducibility: The t test was performed on the two data set obtained from two different 
instruments and compared with tabulated value. There was no significant difference was judged. 
Table 5: Reproducibility study of TOLP (50 µg/ml) 
Instrument 1 Instrument 2 Result of t test* Inference 
2300960.912±27899.614 2322036.197±30331.080 0.185 No significant difference
* At 95% confidence interval, (t-Tabulated = 2.45) 
3.1.8 Robustness: The % of RSD of robustness testing under different altered conditions is given in 
Table 6, indicating that the current method is robust. 
Table 6: Robustness evaluation of the proposed method. 
Parameter Conditions Amount of TOLP added (µg/ml) 
Amount of TOLP detected 
(Mean ± SD) %RSD 
Change in 
mobile phase 
composition 
ACN : Buffer = 53:47 50 49.61 ± 0.47 0.95 
ACN : Buffer = 55:45 50 49.55 ± 0.01 0.02 
ACN : Buffer = 57:43 50 49.32 ± 0.39 0.79 
Change in 
flow rate 
0.9ml/min 50 49.92 ± 0.02 0.04 
1.0 ml/min 50 49.88 ± 0.01 0.02 
1.1 ml/min 50 49.67 ± 0.04 0.08 
3.2 Determination of TOLP in marketed formulations: Two marketed formulations of TOLP were 
analyzed by proposed RP-HPLC method and the results of this analysis are shown in Table 7. 
Table 7: Assay of Marketed Formulations of TOLP by proposed RP-HPLC method 
Formulation (Tablet) Actual concentration (µg/ml) Amount obtained (µg/ml) % TOLP 
Brand 1 (Tolpidol®) 50 49.23 98.46 
Brand 2 (Tolfree®) 50 49.70 99.40 
Conclusion 
The proposed RP-HPLC method for estimation 
of Tolperisone Hydrochloride in bulk and in 
tablet dosage form was found to be simple, 
accurate, precise reproducible and highly 
sensitive. The % recovery and specificity study 
show that the method is free from interference of 
the excipients used in formulation. Moreover, 
the lower solvent consumption along with the 
short analytical run time of 5 min leads to cost 
effective chromatographic method. The 
measured signals were shown to be precise, 
accurate and linear over the wide concentration 
range with a correlation coefficient around 
0.999. The % RSD for all parameters were 
found to be less than two, which indicates the 
validity of method and assay result obtained by 
this method is in fair agreement. Therefore it 
seems to be suitable for the routine quality 
control analysis in analytical lab. 
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